“While personalized IBD supplement protocols have been game-changing, it’s essential to recognize that conducting follow-ups and making regular dose adjustments are equally crucial aspects of patient care. The team behind Evinature recognize every IBD patient’s need for emotional support and a credible source of medical information, leading to the inception of Clinic Support.”
Evinature’s Clinic Support Introduces A New Era of IBD Patient Care
“This collaboration demonstrates Adacyte´s strategy of leveraging our expertise in IBD to continue providing innovative and distinctive solutions. We believe even more strongly that Evinature´s unique compound, CurQD, can become a fundamental treatment option for patients and physicians struggling to control IBD.”
Christian Izcara, Managing Director at Adacyte.
“Using their gold standard in providing each patient with a tailor-fit solution, Evinature goes through an academically rigorous peer review process to ensure the validity of traditional remedies. Evinature has gone leaps and bounds further into proving misconceptions about traditional medicine with the ultimate goal of prioritising global accessibility for patients who could not afford treatment otherwise.”
Promising Strategies to Improve Patient Quality of Life
“Sheba is very appreciative of the advanced research ongoing in the GI Department to explore herbal-based innovative strategies to help patients with chronic disorders, and we are excited that we are now able to provide these solutions to patients worldwide through the Sheba spinoff company, Evinature”
Yoel Har-Even, Director of Sheba Global
“A very promising and nicely conducted trial. There is a lot of interest in rigorous studies of non-immunosuppressive treatments that may still be effective in relieving objective inflammation (apart from just symptomatic improvement). This study provides a nice evidence base for that.”
Ashwin N. Ananthakrishnan, MBBS, MPH, Massachusetts General Hospital.
“These results are clearly exciting… It will be extremely important to understand the reproducibility of this effect in the future and the effect in various subpopulations of IBD.”
Byron Vaughn, MD, associate professor of medicine & co-director of the IBD program, University of Minnesota.
